Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow LAVA Therapeutics NV

Get SEC filing alerts via email and in your feed for LAVA Therapeutics NV

LVTX

LAVA Therapeutics NV

About LAVA Therapeutics NV

LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company developing Gammabody bispecific antibodies that engage gamma delta (gd) T cells to target and kill cancer cells. Its platform offers off-the-shelf, tumor-specific therapies with potential for durable responses and fewer toxicities. The company focuses on hematologic malignancies and solid tumors, leveraging strategic partnerships and proprietary technology to advance targeted, immune-activating cancer treatments.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from LAVA Therapeutics NV

1
1
LAVA Therapeutics NV LAVA Therapeutics Reports No Revenue and $7.19 Million Net Loss in Latest Quarter

Via official filing (AI summary) | 8 months ago | 0 comments

2
1
LAVA Therapeutics NV LAVA Therapeutics Reports $12.1 Million Net Loss and Revenue Decline in First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

3
1
LAVA Therapeutics NV LAVA Therapeutics Reports $0 Revenue and Widened Losses in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
LAVA Therapeutics NV LAVA Therapeutics Reports $25.1 Million Net Loss and Revenue Growth to $12.0 Million for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments